1 not yet recruiting, 1 recruiting, 1 terminated, 1 unknown. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Not yet recruiting 1, Recruiting 1, Terminated 1, Unknown 1 |
Follow Sinew Pharma Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Randomized, Double-Blind, Placebo Controlled Study to Assess the Efficacy and Safety of SNP-610 for the Treatment of Patients With Non-alcoholic Steatohepatitis SNP-610, Placebo Oral Tablet - NASH - Nonalcoholic Steatohepatitis | Phase 2 | Not yet recruiting | Sinew Pharma Inc. | 80 | 2026-04-01 | 2026-03-18 |
| A Novel, Potent and Non-addictive Analgesic of Combinations for Knee Replacement Moderate to Severe Pain Management Naldebain, SafeTynadol, Naldebain + SafeTynadol - Pain, Postoperative | Phase 2 | Unknown | Sinew Pharma Inc. | 36 | 2023-07-25 | 2023-07-27 |
| To Evaluate the Efficacy and Safety of TYNADOTE® in the Treatment of Acetaminophen Overdose TYNADOTE, Placebo Oral Tablet - Hepatitis | Phase 2 | Recruiting | Sinew Pharma Inc. | 24 | 2023-05-01 | 2024-01-10 |
| An Open-Label Study to Assess the Hepatic Protection Effect of SNP-612, in Patients With NAFLD SNP-612 dose1, SNP-612 dose2 - NASH - Nonalcoholic Steatohepatitis | Phase 2 | Terminated | Sinew Pharma Inc. | 90 | 2017-08-04 | 2023-01-06 |
Non-alcoholic Fatty Liver Disease (2) · Hepatitis (1) · Liver Failure, Acute (1) · Pain, Postoperative (1)
Taiwan (3)
Cheng-Fong Mr Chen, PhD (1) · Yu-Lueng Shih, MD,PhD (1)